<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="63320a27-e723-4b3b-9210-3f2e67444870"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use AK-FLUOR<sup>®</sup> 10% safely and effectively. See full prescribing information for AK-FLUOR® (fluorescein injection, USP) 10% Intravenous Injection.<br/>Initial U.S. Approval: 1976
</title>
   <effectiveTime value="20241206"/>
   <setId root="73511e79-c050-4dc0-aa2f-a79ed320b5b0"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="081134465" root="1.3.6.1.4.1.519.1"/>
            <name>Long Grove Pharmaceuticals, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="e49885ce-b609-4ac4-b97c-00b976277210"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241206"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="81298-8660" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AK-FLUOR</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>fluorescein</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="93X55PE38X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>fluorescein sodium</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TPY09G7XIR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>fluorescein</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydrochloric acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="81298-8660-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="12" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="81298-8660-3" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240928"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240928"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022186" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="21affe39-0d9d-437e-aec4-69ffb192b8fd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>AK-FLUOR<sup>®</sup> 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.
</paragraph>
               </text>
               <effectiveTime value="20241206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>AK-FLUOR<sup>®</sup> is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. (<linkHtml href="#s1">1</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="68412365-66cf-4283-8fe1-7b3b186c3411"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20241206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The normal adult dose of AK-FLUOR<sup>®</sup> 10% is 5 mL (500 mg) via intravenous administration. (<linkHtml href="#s3">2.1</linkHtml>)
</item>
                           <item>For children, the dose should be calculated on the basis of 35 mg for each ten pounds of body weight (7.7 mg/kg body weight). (<linkHtml href="#s6">2.2</linkHtml>)
</item>
                           <item>Do not mix or dilute with other solutions or drugs. (<linkHtml href="#s6">2.2</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="7aeddc92-8c05-47b4-8e21-9d82915c25c7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Dosing
</title>
                     <effectiveTime value="20241206"/>
                     <component>
                        <section ID="s4">
                           <id root="459843fb-7e74-4c5e-bbe7-75b8c9a7d73e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Adult Dose</content>
                              </paragraph>
                              <paragraph>The recommended dosage of AK-FLUOR<sup>®</sup> 10% (100 mg/mL) is 500 mg via intravenous administration.
</paragraph>
                           </text>
                           <effectiveTime value="20241206"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s5">
                           <id root="7b66bb90-bcd8-45d2-bd8c-f5c98d8b5f3a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Pediatric Dose</content>
                              </paragraph>
                              <paragraph>For children, the dose is 7.7 mg/kg (actual body weight) up to a maximum of 500 mg, via intravenous infusion calculated on the basis of 35 mg for each 10 lbs. (4.54 kg) of body weight.
</paragraph>
                           </text>
                           <effectiveTime value="20241206"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="85c20916-11c8-44ad-8bf9-d7ccb0932c0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Preparation for Administration
</title>
                     <text>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not mix or dilute with other solutions or drugs.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="4c90ba11-59ef-49f7-9e9b-295f936bfb35"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Administration
</title>
                     <text>
                        <paragraph>Inject the dose (over 5-10 seconds is normally recommended) into the antecubital vein, after taking precautions to avoid extravasation. A syringe, filled with AK-FLUOR<sup>®</sup>, may be attached to transparent tubing and a 23 gauge butterfly needle for injection. Insert the needle and draw the patient's blood to the hub of the syringe so that a small air bubble separates the patient's blood in the tubing from the fluorescein. With the room lights on, slowly inject the blood back into the vein while watching the skin over the needle tip. If the needle has extravasated, the patient's blood will be seen to bulge the skin and the injection should be stopped before any fluorescein is injected. When assured that extravasation has not occurred, the room light may be turned off and the fluorescein injection completed. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds and can be observed by standard viewing equipment.
</paragraph>
                        <paragraph>Reduction in dose from 500 mg to 200 mg of AK-FLUOR® 10% may be appropriate in cases when a highly sensitive imaging system e.g., scanning laser ophthalmoscope is used.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="60c3d1ec-a63e-41b4-a258-ceae04dff73c"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>AK-FLUOR<sup>®</sup> (fluorescein injection, USP) 10%, 500 mg/ 5mL (100 mg/ml) is a dark reddish orange, clear solution in a 5 mL single-dose vial.
</paragraph>
               </text>
               <effectiveTime value="20241206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>AK-FLUOR<sup>®</sup> (fluorescein injection, USP) 10%, 500 mg/ 5mL (100 mg/mL) is a dark reddish orange, clear solution in a 5 mL single dose vial (<linkHtml href="#s8">3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="0d6d1fae-b44a-4948-a94c-68c8452a4e8f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <effectiveTime value="20241206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity to any component of this product. (<linkHtml href="#s10">4.1</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s10">
                     <id root="0917dedb-eeec-4c00-92e2-d015a6c3eb02"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Hypersensitivity
</title>
                     <text>
                        <paragraph>AK-FLUOR<sup>®</sup> is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported [see <content styleCode="italics">Warnings and Precautions</content> (<linkHtml href="#s12">5.1</linkHtml>) and <content styleCode="italics">Adverse Reactions</content> (<linkHtml href="#s16">6.2</linkHtml>)].
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="6e77e11f-068b-4f62-a78c-313cf1d60b89"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20241206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Respiratory reactions (<linkHtml href="#s12">5.1</linkHtml>)
</item>
                           <item>Severe local tissue damage (<linkHtml href="#s13">5.2</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s12">
                     <id root="f0454178-4174-433d-b742-83eaea44ca13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Respiratory Reactions
</title>
                     <text>
                        <paragraph>Caution should be exercised in patients with a history of allergy or bronchial asthma. An emergency tray should always be available.
</paragraph>
                        <paragraph>If a potential allergy is suspected, an intradermal skin test may be performed prior to intravenous administration, i.e., 0.05 mL injected intradermally to be evaluated 30 to 60 minutes following injection. Given the sensitivity and specificity of skin testing, a negative skin test is not proof that a patient is not allergic to fluorescein.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="83f2eccd-f151-4ab4-92fb-7b97f838fe12"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Severe local tissue damage
</title>
                     <text>
                        <paragraph>Extravasation during injection can result in severe local tissue damage due to high pH of fluorescein solution. The following complications resulting from extravasation of fluorescein have been noted to occur: Sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median nerve in the antecubital area. Complications resulting from extravasation can cause severe pain in the arm for up to several hours. When extravasation occurs, the injection should be discontinued and conservative measures to treat damaged tissue and to relieve pain should be implemented. [see <content styleCode="italics">Administration (2.3</content>) and <content styleCode="italics">Adverse Reactions (<linkHtml href="#s20">6.6</linkHtml>)</content>].
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="7192fe29-9391-4acf-aadf-29185e2e288f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <effectiveTime value="20241206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions include skin discoloration, urine discoloration, nausea, vomiting, and gastrointestinal distress
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Long Grove Pharmaceuticals, LLC at 1-855-642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (<linkHtml href="#s14">6</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s15">
                     <id root="18a3f4fc-6b51-40a7-99cc-3ba44e839593"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Skin and urine discoloration
</title>
                     <text>
                        <paragraph>The most common reaction is discoloration of the skin and urine. Skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="1c1da69f-85fa-45fe-ac5e-ed58aeb10dd6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Gastrointestinal Reaction
</title>
                     <text>
                        <paragraph>The next most common adverse reaction is nausea. Vomiting, and gastrointestinal distress have also occurred. A strong taste may develop after injection.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="afa6f064-6d5f-4505-9ebd-339328595860"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Hypersensitivity Reactions
</title>
                     <text>
                        <paragraph>Symptoms and signs of hypersensitivity have occurred. Generalized hives and itching, bronchospasm and anaphylaxis have been reported. [see <content styleCode="italics">Contraindications (<linkHtml href="#s10">4.1</linkHtml>)</content> and <content styleCode="italics">Warnings and Precautions (<linkHtml href="#s12">5.1</linkHtml>)</content>]
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="3e8c0f63-96ba-4082-be90-c355e52a7a6a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.4 Cardiopulmonary Reactions
</title>
                     <text>
                        <paragraph>Syncope and hypotension may occur. Cardiac arrest, basilar artery ischemia, severe shock and death may occur rarely. [see Warnings and Precautions (<linkHtml href="#s12">5.1</linkHtml>)]
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="54e36829-3b6b-4f72-adfc-082f7dd19c37"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.5 Neurologic Reactions
</title>
                     <text>
                        <paragraph>Headache may occur. Convulsions may rarely occur following injection.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="f43a3826-39e2-430b-ae58-58012f6949e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.6 Thrombophlebitis
</title>
                     <text>
                        <paragraph>Thrombophlebitis at the injection site has been reported. Extravasation of the solution at the injection site causes intense pain at the site and a dull aching pain in the injected arm. [see <content styleCode="italics">Administration (<linkHtml href="#s7">2.3</linkHtml>)</content> and <content styleCode="italics">Warnings and Precautions (<linkHtml href="#s13">5.2</linkHtml>)</content>].
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="266df6af-b595-4520-b37e-799113162c8c"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20241206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Caution should be exercised when fluorescein sodium is administered to a nursing woman. (<linkHtml href="#s23">8.3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s22">
                     <id root="b133b7f8-a2a0-4141-ac0e-312bc7ad219e"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <text>
                        <paragraph>Pregnancy Category C. Adequate animal reproduction studies have not been conducted with fluorescein sodium. It is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. Fluorescein sodium should be given to a pregnant woman only if clearly needed.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="ed98bb5f-a050-41ce-a5f6-4106d44ea6a2"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers
</title>
                     <text>
                        <paragraph>Fluorescein sodium has been demonstrated to be excreted in human milk. Caution should be exercised when fluorescein sodium is administered to a nursing woman.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="d6831872-4f69-412d-ba69-9fab58c38c98"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>Pediatric patients have been included in clinical studies. No overall differences in safety or effectiveness have been observed between pediatric and adult patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="6050439b-920d-4f22-a34c-ac18f864d52a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s26">
               <id root="250fddff-b5fc-4492-b7e2-aa3d5151602e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>AK-FLUOR<sup>®</sup> (fluorescein injection, USP) is a sterile solution for use intravenously as a diagnostic aid. It is a dark reddish orange solution with a pH of 8.3 to 9.8 and an osmolality of 572 to 858 mOsm/kg.
</paragraph>
                  <paragraph>Its chemical name is spiro[isobenzofuran-1 (3H),9'-[9H]xanthene]-3-one,3'6'- dihydroxy, disodium salt.: The active ingredient is represented by the chemical structure:
</paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  </paragraph>
                  <paragraph>MW = 376.27
</paragraph>
                  <paragraph>AK-FLUOR® 10% contains:
</paragraph>
                  <paragraph>Active: fluorescein sodium (10 % w/v, 100 mg/mL)
</paragraph>
                  <paragraph>Inactives: Sodium Hydroxide and/or Hydrochloric Acid may be used to adjust pH (8.3 to 9.8), and Water for Injection.
</paragraph>
               </text>
               <effectiveTime value="20241206"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Chemical Structure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="akx00-0001-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="e63aaa1e-4f28-488c-baec-eb1080fa5765"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20241206"/>
               <component>
                  <section ID="s28">
                     <id root="71d282cd-d7e0-40d9-89d6-024d34c4d796"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
               <component>
                  <section ID="s29">
                     <id root="d1e8f739-0f0c-4062-affb-038760a00668"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <effectiveTime value="20241206"/>
                     <component>
                        <section ID="s30">
                           <id root="d983395d-d5f6-4808-8763-a706641b1a7b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Distribution.
</paragraph>
                              <paragraph>Within 7 to 14 seconds after IV administration into the antecubital vein, fluorescein usually appears in the central retinal artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade 6 to 12 hours after dosing. Various estimates of volume of distribution indicate that fluorescein distributes into interstitial space (0.5 L/kg).
</paragraph>
                           </text>
                           <effectiveTime value="20241206"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s31">
                           <id root="79e1af40-f77a-4156-b10d-e2360e5e459f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Metabolism.
</paragraph>
                              <paragraph>Fluorescein is metabolized to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose.
</paragraph>
                           </text>
                           <effectiveTime value="20241206"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s32">
                           <id root="f9e76891-3623-47ce-bc9b-ae1b9c1807bf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Excretion.
</paragraph>
                              <paragraph>Fluorescein and its metabolite are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.
</paragraph>
                           </text>
                           <effectiveTime value="20241206"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s33">
               <id root="8620dc5d-41d7-4676-a461-0c501e305085"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20241206"/>
               <component>
                  <section ID="s34">
                     <id root="b1b86ac2-73c0-4878-9e95-5554bbbcd193"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>There have been no long-term studies done using fluorescein in animals to evaluate carcinogenic potential.
</paragraph>
                     </text>
                     <effectiveTime value="20241206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s35">
               <id root="e6c161e8-c21d-4791-96af-3c993567dba2"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>AK-FLUOR® (fluorescein injection, USP) 10%, 500 mg/5 mL (100mg/mL) is supplied in a single-dose 5 mL glass vial with a gray chlorobutyl serum siliconized stopper and orange flip-off cap. It contains a sterile dark reddish orange solution of fluorescein sodium.
</paragraph>
                  <paragraph>(NDC 81298-8660-3) 5 mL, single dose vials in a package of 12.
</paragraph>
                  <paragraph>AK-FLUOR® should be stored at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Discard unused portion.
</paragraph>
               </text>
               <effectiveTime value="20241206"/>
            </section>
         </component>
         <component>
            <section ID="s36">
               <id root="e013a430-a9d4-48d2-acd8-f734a7f8bd5f"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#s15">6.1</linkHtml>)</content>].
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Long Grove Pharmaceuticals, LLC</content>
                     <br/>Rosemont, IL 60018
</paragraph>
                  <paragraph>Made in India<br/>US/LF/077 V02       Rev. 12/24<br/>PLF199/01
</paragraph>
               </text>
               <effectiveTime value="20241206"/>
            </section>
         </component>
         <component>
            <section ID="s37">
               <id root="6d85c603-7903-40f4-a5d2-2f885c2d5c0f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel – 5 mL Carton Label</content>
                  </paragraph>
                  <paragraph>NDC 81298-<content styleCode="bold">8660</content>-3
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>
                     <content styleCode="bold">AK-FLU0R</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">10%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Fluorescein Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg/5 mL (100 mg/mL) / 12 Sterile Vials (5mL each)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">LONG GROVE™</content>
                     <br/>PHARMACEUTICALS
</paragraph>
                  <renderMultiMedia ID="f02" referencedObject="mm02"/>
               </text>
               <effectiveTime value="20241206"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Principal Display Panel – 5 mL Carton Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="akx00-0001-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s38">
               <id root="a13b19f0-d65b-4d87-ba79-6dfd5b5583d8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel – 5 mL Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 81298-<content styleCode="bold">8660</content>-1
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>
                     <content styleCode="bold">AK-FLU0R</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">10%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Fluorescein Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg/5 mL (100 mg/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL Sterile Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Injection</content>
                  </paragraph>
                  <renderMultiMedia ID="f03" referencedObject="mm03"/>
               </text>
               <effectiveTime value="20241206"/>
               <component>
                  <observationMedia ID="mm03">
                     <text>Principal Display Panel – 5 mL Vial Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="akx00-0001-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>